Loading…
Lobbying Spend
—
Filings
18
Firms Hired
1
Active Period
2022–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. H.R. 4408/S. 1906, Promising Pathway Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 4408
Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. H.R. 4408/S. 1906, Promising Pathway Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 1906
Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. H.R. 4408/S. 1906, Promising Pathway Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 4408
Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. H.R. 4408/S. 1906, Promising Pathway Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 1906
Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. H.R. 4408/S. 1906, Promising Pathway Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 4408
Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. H.R. 4408/S. 1906, Promising Pathway Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 1906
Source: Senate LDA